RU2270680C2 - Применение миртазапина для лечения расстройств сна - Google Patents
Применение миртазапина для лечения расстройств сна Download PDFInfo
- Publication number
- RU2270680C2 RU2270680C2 RU2002124141/15A RU2002124141A RU2270680C2 RU 2270680 C2 RU2270680 C2 RU 2270680C2 RU 2002124141/15 A RU2002124141/15 A RU 2002124141/15A RU 2002124141 A RU2002124141 A RU 2002124141A RU 2270680 C2 RU2270680 C2 RU 2270680C2
- Authority
- RU
- Russia
- Prior art keywords
- mirtazapine
- sleep
- treatment
- dose
- administered
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960001785 mirtazapine Drugs 0.000 title claims abstract description 46
- 208000019116 sleep disease Diseases 0.000 title description 24
- 208000020685 sleep-wake disease Diseases 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 18
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 11
- 206010022437 insomnia Diseases 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims abstract 3
- 238000011287 therapeutic dose Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000007958 sleep Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 230000003860 sleep quality Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010072269 Egocentrism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- -1 patch Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200499 | 2000-02-11 | ||
| EP00200499.2 | 2000-02-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002124141A RU2002124141A (ru) | 2004-03-10 |
| RU2270680C2 true RU2270680C2 (ru) | 2006-02-27 |
Family
ID=8171013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002124141/15A RU2270680C2 (ru) | 2000-02-11 | 2001-02-06 | Применение миртазапина для лечения расстройств сна |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6933293B2 (enExample) |
| EP (4) | EP1656937A1 (enExample) |
| JP (1) | JP5039994B2 (enExample) |
| KR (1) | KR20020069371A (enExample) |
| CN (2) | CN1395487A (enExample) |
| AR (1) | AR027394A1 (enExample) |
| AT (1) | ATE317261T1 (enExample) |
| AU (1) | AU780439B2 (enExample) |
| BR (1) | BR0108261A (enExample) |
| CA (1) | CA2396209C (enExample) |
| CO (1) | CO5271706A1 (enExample) |
| CZ (1) | CZ302368B6 (enExample) |
| DE (1) | DE60117122T2 (enExample) |
| DK (1) | DK1257278T3 (enExample) |
| ES (1) | ES2258071T3 (enExample) |
| HK (1) | HK1049122B (enExample) |
| HU (1) | HUP0204391A3 (enExample) |
| IL (2) | IL150290A0 (enExample) |
| NO (1) | NO328007B1 (enExample) |
| PE (1) | PE20011080A1 (enExample) |
| PL (1) | PL206073B1 (enExample) |
| RU (1) | RU2270680C2 (enExample) |
| SK (1) | SK287396B6 (enExample) |
| WO (1) | WO2001058453A1 (enExample) |
| ZA (1) | ZA200205238B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040152055A1 (en) * | 2003-01-30 | 2004-08-05 | Gliessner Michael J.G. | Video based language learning system |
| UA83666C2 (ru) | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| EP1689371A2 (en) * | 2003-11-25 | 2006-08-16 | Aurobindo Pharma Limited | Pharmaceutical compositions of mirtazapine |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1806133A1 (en) * | 2004-10-14 | 2007-07-11 | Daikin Industries, Ltd. | Method for modifying the ambience, and spray liquid and sprayer used in the method |
| JP2006137748A (ja) * | 2004-10-14 | 2006-06-01 | Daikin Ind Ltd | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 |
| JP2007284363A (ja) * | 2006-04-13 | 2007-11-01 | Daikin Ind Ltd | 噴霧剤 |
| CN101679431B (zh) | 2007-04-11 | 2013-08-14 | Msd欧斯股份有限公司 | 制备四环苯并氮杂卓的对映异构体的方法 |
| JP6876003B2 (ja) | 2015-02-27 | 2021-05-26 | デクラ リミテッド | イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置 |
| CN111053735A (zh) * | 2020-02-25 | 2020-04-24 | 上海阶平医院管理有限公司 | 一种治疗失眠的冷敷凝胶 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2107058C1 (ru) * | 1992-10-07 | 1998-03-20 | Акцо Нобель Н.В. | Способ выделения энантиомеров из рацемической смеси |
| WO1999025356A1 (en) * | 1997-11-14 | 1999-05-27 | Akzo Nobel N.V. | Use of mirtazapine for treating sleep apneas |
| RU97110083A (ru) * | 1996-06-19 | 1999-05-27 | Акцо Нобель Н.В. | Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| EP0813873B1 (en) | 1996-06-19 | 2002-02-13 | Akzo Nobel N.V. | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
-
2001
- 2001-02-06 EP EP05109547A patent/EP1656937A1/en not_active Ceased
- 2001-02-06 IL IL15029001A patent/IL150290A0/xx unknown
- 2001-02-06 DE DE60117122T patent/DE60117122T2/de not_active Expired - Lifetime
- 2001-02-06 CN CN01803934A patent/CN1395487A/zh active Pending
- 2001-02-06 CN CNA2008100056868A patent/CN101229170A/zh active Pending
- 2001-02-06 AU AU30247/01A patent/AU780439B2/en not_active Expired
- 2001-02-06 EP EP10178745A patent/EP2283840A1/en not_active Withdrawn
- 2001-02-06 SK SK1144-2002A patent/SK287396B6/sk not_active IP Right Cessation
- 2001-02-06 HK HK03101379.6A patent/HK1049122B/en not_active IP Right Cessation
- 2001-02-06 DK DK01902410T patent/DK1257278T3/da active
- 2001-02-06 WO PCT/EP2001/001221 patent/WO2001058453A1/en not_active Ceased
- 2001-02-06 BR BR0108261-2A patent/BR0108261A/pt not_active Application Discontinuation
- 2001-02-06 EP EP01902410A patent/EP1257278B1/en not_active Expired - Lifetime
- 2001-02-06 JP JP2001557563A patent/JP5039994B2/ja not_active Expired - Lifetime
- 2001-02-06 RU RU2002124141/15A patent/RU2270680C2/ru not_active IP Right Cessation
- 2001-02-06 AT AT01902410T patent/ATE317261T1/de active
- 2001-02-06 EP EP05109549A patent/EP1658850A1/en not_active Withdrawn
- 2001-02-06 US US10/203,232 patent/US6933293B2/en not_active Expired - Lifetime
- 2001-02-06 ES ES01902410T patent/ES2258071T3/es not_active Expired - Lifetime
- 2001-02-06 CZ CZ20022330A patent/CZ302368B6/cs not_active IP Right Cessation
- 2001-02-06 CA CA002396209A patent/CA2396209C/en not_active Expired - Lifetime
- 2001-02-06 HU HU0204391A patent/HUP0204391A3/hu unknown
- 2001-02-06 KR KR1020027009536A patent/KR20020069371A/ko not_active Ceased
- 2001-02-06 PL PL356721A patent/PL206073B1/pl not_active IP Right Cessation
- 2001-02-08 PE PE2001000141A patent/PE20011080A1/es not_active Application Discontinuation
- 2001-02-09 AR ARP010100585A patent/AR027394A1/es unknown
- 2001-02-09 CO CO01009904A patent/CO5271706A1/es not_active Application Discontinuation
-
2002
- 2002-06-18 IL IL150290A patent/IL150290A/en not_active IP Right Cessation
- 2002-06-28 ZA ZA200205238A patent/ZA200205238B/en unknown
- 2002-08-09 NO NO20023803A patent/NO328007B1/no not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2107058C1 (ru) * | 1992-10-07 | 1998-03-20 | Акцо Нобель Н.В. | Способ выделения энантиомеров из рацемической смеси |
| RU97110083A (ru) * | 1996-06-19 | 1999-05-27 | Акцо Нобель Н.В. | Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка |
| WO1999025356A1 (en) * | 1997-11-14 | 1999-05-27 | Akzo Nobel N.V. | Use of mirtazapine for treating sleep apneas |
Non-Patent Citations (2)
| Title |
|---|
| Р.С. Сатоскар, С.Д. Бандаркар. Фармакология и фармакотерапия. - М.: Медицина, 1986, т.1, с.57. * |
| Реферат Medline: Sorensen M. et al. A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta. Psychiatr. Scand. 1985 Apr; 71(4): 339-46. Неврология. Под ред. М.Самуэльса. - M.: Практика, 1997, с.35-38, 175-178. АЖГИХИН И.С. Технология лекарств. - M.: Медицина, 1975, с.112-113. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| US12485100B2 (en) | Treatment of menstrual cycle-induced symptoms | |
| EP1732530A1 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
| CA2396209C (en) | The use of mirtazapine for the treatment of sleep disorders | |
| MOK et al. | Multidose/observational, comparative clinical analgetic evaluation of buprenorphine | |
| KR20250008060A (ko) | 발작 장애의 치료 | |
| HK1087356A (en) | The use of mirtazapine for the treatment of sleep disorders | |
| HK1150978A (en) | The use of mirtazapine for the treatment of sleep disorders | |
| HK1087359A (en) | The use of mirtazapine for the treatment of sleep disorders | |
| MXPA02006710A (en) | The use of mirtazapine for the treatment of sleep disorders | |
| HK40075517A (en) | Treatment of menstrual cycle-induced symptoms | |
| HK40075517B (en) | Treatment of menstrual cycle-induced symptoms | |
| Dhorranintra et al. | A Study on eNS-Side Effects of Meq, uitazine, An H1-Specific Antihistamine in Healthy Thai Volunteers | |
| Zarattini et al. | P-2-115 Clinical efficacy of paroxetine in elderly outpatients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20070416 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120207 |